---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-007839"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:31:42.859548+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences enrolls first patients in thyroid cancer feasibility study of Vybrance nsPFA system

## Summary
- First-in-human cases completed at Sarasota Memorial and MD Anderson for T1N0M0 papillary thyroid microcarcinoma.
- Study is a multicenter, prospective feasibility trial; 30 patients planned across two sites.
- System has FDA 510(k) clearance for soft tissue ablation; study runs under IDE for thyroid indications.
- Primary endpoints: safety and effectiveness of nsPFA in treating tumors <1.5 cm.

## SEC filing metadata
- accession: 0001437749-26-007839
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926007839/0001437749-26-007839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926007839/plse20260309_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-007839
- JSON: https://secwatch.observer/filing/0001437749-26-007839.json
- Plain text: https://secwatch.observer/filing/0001437749-26-007839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.